Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development $ 12,214 $ 7,704
General and administrative 3,700 2,514
Total operating expenses 15,914 10,218
Operating loss (15,914) (10,218)
Non-operating income (expense):    
Interest and other income, net 1,404 400
Loss from change in fair value of derivative liability (14) (13)
Total non-operating income, net 1,390 387
Net loss (14,524) (9,831)
Other comprehensive income:    
Net unrealized gain on available-for-sale marketable debt securities 67  
Comprehensive loss $ (14,457) $ (9,831)
Net loss per common share - basic (in dollars per share) $ (0.28) $ (0.19)
Net loss per common share - diluted (in dollars per share) $ (0.28) $ (0.19)
Weighted average number of common shares outstanding - basic (in shares) 51,409 50,528
Weighted average number of common shares outstanding - diluted (in shares) 51,409 50,528